424 related articles for article (PubMed ID: 26733306)
41. JUND-dependent up-regulation of HMOX1 is associated with cisplatin resistance in muscle-invasive bladder cancer.
Peng Y; Chen Y; Chen S; Wang J; Jiang C; Hou W; Xu C
J Biochem; 2020 Jul; 168(1):73-82. PubMed ID: 32240302
[TBL] [Abstract][Full Text] [Related]
42. Transcribed ultraconserved region Uc.63+ promotes resistance to cisplatin through regulation of androgen receptor signaling in bladder cancer.
Sekino Y; Sakamoto N; Ishikawa A; Honma R; Shigematsu Y; Hayashi T; Sentani K; Oue N; Teishima J; Matsubara A; Yasui W
Oncol Rep; 2019 May; 41(5):3111-3118. PubMed ID: 30864720
[TBL] [Abstract][Full Text] [Related]
43. Effect of cisplatin-based neoadjuvant chemotherapy on survival in patients with bladder cancer: a meta-analysis.
Li G; Niu HM; Wu HT; Lei BY; Wang XH; Guo XB; Feng SL
Clin Invest Med; 2017 Apr; 40(2):E81-E94. PubMed ID: 28447581
[TBL] [Abstract][Full Text] [Related]
44. The tumor suppressor maspin mediates E2F1-induced sensitivity of cancer cells to chemotherapy.
Ben Shachar B; Feldstein O; Hacohen D; Ginsberg D
Mol Cancer Res; 2010 Mar; 8(3):363-72. PubMed ID: 20197383
[TBL] [Abstract][Full Text] [Related]
45. Increased expression of transcription factor TFAP2α correlates with chemosensitivity in advanced bladder cancer.
Nordentoft I; Dyrskjøt L; Bødker JS; Wild PJ; Hartmann A; Bertz S; Lehmann J; Orntoft TF; Birkenkamp-Demtroder K
BMC Cancer; 2011 Apr; 11():135. PubMed ID: 21489314
[TBL] [Abstract][Full Text] [Related]
46. miRNAs associated with chemo-sensitivity in cell lines and in advanced bladder cancer.
Nordentoft I; Birkenkamp-Demtroder K; Agerbæk M; Theodorescu D; Ostenfeld MS; Hartmann A; Borre M; Ørntoft TF; Dyrskjøt L
BMC Med Genomics; 2012 Sep; 5():40. PubMed ID: 22954303
[TBL] [Abstract][Full Text] [Related]
47. Inhibition of bcl-2 enhances the efficacy of chemotherapy in renal cell carcinoma.
Kausch I; Jiang H; Thode B; Doehn C; Krüger S; Jocham D
Eur Urol; 2005 May; 47(5):703-9. PubMed ID: 15826766
[TBL] [Abstract][Full Text] [Related]
48. Phosphatidylinositol- 3-kinase inhibitor induces chemosensitivity to a novel derivative of doxorubicin, AD198 chemotherapy in human bladder cancer cells in vitro.
Smolensky D; Rathore K; Cekanova M
BMC Cancer; 2015 Nov; 15():927. PubMed ID: 26597249
[TBL] [Abstract][Full Text] [Related]
49. Cis-dichlorodiammineplatinum upregulates angiotensin II type 1 receptors through reactive oxygen species generation and enhances VEGF production in bladder cancer.
Tanaka N; Miyajima A; Kosaka T; Shirotake S; Hasegawa M; Kikuchi E; Oya M
Mol Cancer Ther; 2010 Nov; 9(11):2982-92. PubMed ID: 20978160
[TBL] [Abstract][Full Text] [Related]
50. Low ERCC1 expression is associated with prolonged survival in patients with bladder cancer receiving platinum-based neoadjuvant chemotherapy.
Ozcan MF; Dizdar O; Dincer N; Balcı S; Guler G; Gok B; Pektas G; Seker MM; Aksoy S; Arslan C; Yalcin S; Balbay MD
Urol Oncol; 2013 Nov; 31(8):1709-15. PubMed ID: 22863869
[TBL] [Abstract][Full Text] [Related]
51. Cigarette Smoke Containing Acrolein Contributes to Cisplatin Resistance in Human Bladder Cancers through the Regulation of HER2 Pathway or FGFR3 Pathway.
Hong JH; Tong ZJ; Wei TE; Lu YC; Huang CY; Huang CY; Chiang CH; Jaw FS; Cheng HW; Wang HT
Mol Cancer Ther; 2022 Jun; 21(6):1010-1019. PubMed ID: 35312783
[TBL] [Abstract][Full Text] [Related]
52. Neoadjuvant chemotherapy with docetaxel and cisplatin in patients with high-risk resectable bladder carcinoma: long term results.
Bamias A; Deliveliotis C; Karayiannis A; Varkarakis I; Zervas I; Pantazopoulos D; Gika D; Dimopoulos MA
Eur Urol; 2004 Sep; 46(3):344-50; discussion 350-1. PubMed ID: 15306106
[TBL] [Abstract][Full Text] [Related]
53. Expression and Functions of Formyl Peptide Receptor 1 in Drug-Resistant Bladder Cancer.
Jiang X; Lei T; Zhang M
Technol Cancer Res Treat; 2018 Jan; 17():1533034618769413. PubMed ID: 29665744
[TBL] [Abstract][Full Text] [Related]
54. RNA interference-mediated vascular endothelial growth factor-C reduction suppresses malignant progression and enhances mitomycin C sensitivity of bladder cancer T24 cells.
Zhang HH; Qi F; Shi YR; Miao JG; Zhou M; He W; Chen MF; Li Y; Zu XB; Qi L
Cancer Biother Radiopharm; 2012 Jun; 27(5):291-8. PubMed ID: 21902544
[TBL] [Abstract][Full Text] [Related]
55.
Wei W; Sun J; Zhang H; Xiao X; Huang C; Wang L; Zhong H; Jiang Y; Zhang X; Jiang G
Cancer Res; 2021 Dec; 81(24):6142-6156. PubMed ID: 34702726
[TBL] [Abstract][Full Text] [Related]
56. Impact of Methadone on Cisplatin Treatment of Bladder Cancer Cells.
Michalska M; Schultze-Seemann S; Kuckuck I; Katzenwadel A; Wolf P
Anticancer Res; 2018 Mar; 38(3):1369-1375. PubMed ID: 29491061
[TBL] [Abstract][Full Text] [Related]
57. Discovery and Validation of Nitroxoline as a Novel STAT3 Inhibitor in Drug-resistant Urothelial Bladder Cancer.
Lin W; Sun J; Sadahira T; Xu N; Wada K; Liu C; Araki M; Xu A; Watanabe M; Nasu Y; Huang P
Int J Biol Sci; 2021; 17(12):3255-3267. PubMed ID: 34421363
[TBL] [Abstract][Full Text] [Related]
58. Increased expression of TNFRSF14 indicates good prognosis and inhibits bladder cancer proliferation by promoting apoptosis.
Zhu YD; Lu MY
Mol Med Rep; 2018 Sep; 18(3):3403-3410. PubMed ID: 30066919
[TBL] [Abstract][Full Text] [Related]
59. Cisplatin and Paclitaxel Alter the Expression Pattern of miR-143/145 and miR-183/96/182 Clusters in T24 Bladder Cancer Cells.
Papadopoulos EI; Scorilas A
Clin Transl Sci; 2015 Dec; 8(6):668-75. PubMed ID: 26356996
[TBL] [Abstract][Full Text] [Related]
60. miR-222 attenuates cisplatin-induced cell death by targeting the PPP2R2A/Akt/mTOR Axis in bladder cancer cells.
Zeng LP; Hu ZM; Li K; Xia K
J Cell Mol Med; 2016 Mar; 20(3):559-67. PubMed ID: 26800397
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
